Skip to main content
Equibles

RHUMBLINE ADVISERS

Position in EDIT — Editas Medicine, Inc.

CIK 1115418 BOSTON, MA
Back to EDIT Full portfolio

Position in EDIT

as of Jun 30, 2026 · filed Aug 12, 2026
Position Value
$380,431
+$115,647 QoQ
Shares Held
117,417
+9.5% QoQ
Ownership
0.076%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#65
of 216 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 23% Shared 0% None 77%

Common Shares in EDIT Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. EDIT ranks #204 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 396,380 $196,893,837
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,794 $98,390,870
3 MRNA
Moderna, Inc.
 809,853 $56,714,005
4 ALNY
Alnylam Pharmaceuticals, Inc.
 165,579 $49,844,246
5 INCY
Incyte Corp
 428,533 $48,578,500
6 RVMD
Revolution Medicines, Inc.
 226,008 $42,326,778
7 ROIV
Roivant Sciences Ltd.
 1,178,789 $41,717,342
8 JAZZ
Jazz Pharmaceuticals plc
 163,018 $39,282,447

All Filings in EDIT

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $380,431 117,417
2026-03-31 $264,784 107,200
2025-12-31 $224,075 109,305
2025-09-30 $425,165 122,526
2025-06-30 $278,957 126,799
2025-03-31 $143,666 123,850
2024-12-31 $178,710 140,717
2024-09-30 $483,793 141,875
2024-06-30 $644,394 137,986
2024-03-31 $995,200 134,124
2023-12-31 $1,330,940 131,386
2023-09-30 $1,025,068 131,419
2023-06-30 $963,395 117,059
2023-03-31 $807,773 111,417
2022-12-31 $988,898 111,488
2022-09-30 $1,329,349 108,607
2022-06-30 $1,197,822 101,253
2022-03-31 $1,379,805 72,545
2021-12-31 $1,910,776 71,969
2021-09-30 $3,034,620 73,871
2021-06-30 $4,088,841 72,190
2021-03-31 $3,167,094 75,407
2020-12-31 $5,590,641 79,741
2020-09-30 $2,088,197 74,419
2020-06-30 $2,551,748 86,266
2020-03-31 $1,468,689 74,064